DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Adecatumumab
Adecatumumab
Tanibirumab (CUI C3490677) Add to Cart
Development of Novel Bioconjugation Strategies for Creating Cancer-Targeting Nanomaterials
Modifications to the Harmonized Tariff Schedule of the United States To
One Target, Different Effects: a Comparison of Distinct Therapeutic Antibodies Against the Same Targets
(12) Patent Application Publication (10) Pub. No.: US 2017/0172932 A1 Peyman (43) Pub
Download Abstracts
I Regulations
(INN) for Biological and Biotechnological Substances
Targeted Therapy for High-Risk Endometrial Carcinoma
INN Working Document 05.179 Update 2011
Therapeutic Antibody
Stembook 2018.Pdf
A Abacavir Abacavirum Abakaviiri Abagovomab Abagovomabum
(INN) for Biological and Biotechnological Substances
A61K9/51 (2006.01) — with International Search Report (Art
Pharmaceutical Appendix to the Tariff Schedule 2
N° 18380 A61k 31/5377 (2018.01) A61p 35/02 (2018.01)
(12) Patent Application Publication (10) Pub. No.: US 2012/0177568 A1 WILLIAMS Et Al
Top View
(12) United States Patent (10) Patent No.: US 8,815,247 B2 Govindappa Et Al
Customs Tariff - Schedule
Wo 2010/095940 A2
An Overview of the Current Status of Engineered Therapeutic Monoclonal Antibodies
Identification of Pancreatic Cancer-Specific Antigens Using a Novel Quantitative Seroproteomics Approach
Pharmaabkommen A1 E
Biotechnology Presented by America’S Biopharmaceutical Research Companies
(12) United States Patent (10) Patent No.: US 8,563,269 B2 Stagliano Et Al
Epcam Detection
Antibody Therapy of Cancer
An Anti-Epcam Antibody Epab2-6 for the Treatment of Colon Cancer
WO 2014/130879 A2 28 August 2014 (28.08.2014) P O P C T
(12) United States Patent (10) Patent No.: US 9,345,770 B2 Storkus Et Al
The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
In Oncology Lacey R
International Journal of Current Advanced Research
Epithelial Cell Adhesion Molecule: an Anchor to Isolate Clinically Relevant Circulating Tumor Cells
Preclinical Evaluation of VB6-845: an Anti-Epcam Immunotoxin with Reduced Immunogenic Potential
Protein-Polymer-Drug Conjugates Protein-Polymer-Wirkstoffkonjugate Conjugués De Médicament-Protéine-Polymère
(INN) for Biological and Biotechnological Substances
Ep 3088005 A1
Phage Displayed Peptides/Antibodies Recognizing Growth Factors and Their Tyrosine Kinase Receptors As Tools for Anti-Cancer Therapeutics
Targeting Human Cancer Stem Cells with Monoclonal Antibodies
Assessment of the Evolution of Cancer Treatment Therapies
ESMO Poster Stockholm 2008
Timepoint 1 Geting Assembly Complexes (Attacs) for Selectively Activating De¬ Sired Immune Cells in the Tumor Microenvironment
INN-Nimet 1 20.8.2019 a Abacavir Abacavirum Abakaviiri
ASCO Annual Meeting, 2006
Expression and Function of Epithelial Cell Adhesion Molecule Epcam: Where Are We After 40 Years?
Epcam Monoclonal Antibodies
(12) United States Patent (10) Patent No.: US 8,513,390 B2 Stagliano Et Al